News
News
May 30, 2023
AnaptysBio Announces Participation in Upcoming Investor Conferences
May 11, 2023
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
May 2, 2023
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
April 6, 2023
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
March 27, 2023
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
March 1, 2023
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
January 13, 2023
AnaptysBio Announces Stock Repurchase Plan
January 5, 2023
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies